Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis

Abstract

AIM:To clarify whether there is any difference in the symptom relief in patients with reflux esophagitis following the administration of four Proton pump inhibitors (PPIs). METHODS:Two hundred and seventy-four patients with erosive reflux esophagitis were randomized to receive 8 wk of 20 mg omeprazole (n = 68), 30 mg of lansoprazole (n = 69), 40 mg of pantoprazole (n = 69), 40 mg of esomeprazole (n = 68) once a day in the morning. Daily changes in heartburn and acid reflux symptoms in the first 7 d of administration were assessed using a six-point scale (0: none; 1: mild; 2: mild-moderate; 3: moderate; 4: moderate-severe; 5: severe). RESULTS:The mean heartburn score in patients treated with esomeprazole more rapidly decreased than those receiving other PPI. Complete resolution of heartburn was also more rapid in patients treated with esomeprazole for 5 d compared with omeprazole (P = 0.0018, P = 0.0098, P = 0.0027, P = 0.0137, P = 0.0069, respectively), lansoprazole (P = 0.0020, P = 0.0046, P = 0.0037, P = 0.0016, P = 0.0076, respectively), and pantoprazole (P = 0.0006, P = 0.0005, P = 0.0009, P = 0.0031, P = 0.0119, respectively). There were no significant differences between the four groups in the rate of endoscopic healing of reflux esophagitis at week 8. CONCLUSION:Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis.

A randomized, crossover pharmacodynamic study of immediate‐release omeprazole/sodium bicarbonate and delayed‐release lansoprazole in healthy adult volunteers

“…Results of another study (Zheng ), which compared the efficacy of OME, pantoprazole, lansoprazole, and esomeprazole using symptom relief as an endpoint, were consistent with those of a study comparing the effects of the PPIs using intragastric pH as the endpoint (Rohss et al. ).…”

“…Both studies concluded that DR‐esomeprazole 40 mg was more effective than DR‐omeprazole 20 mg, DR‐lansoprazole 30 mg, and DR‐pantoprazole 40 mg (Rohss et al. ; Zheng ). Therefore, whether a true relationship exists between relief of clinical symptoms and control of intragastric pH is unclear.…”

Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers?

“…To sum up, options for prophylaxis include antacids, H2-RAs, sucralfate and PPIs. In order to evaluate the adequacy of dosing these agents, a review of the literature was needed to extract the recommended doses since most of the medications used for SUP are not FDA approved for this indication (Table 2) [9,35,36] . Thus, a prescribed dose was considered correct if it coincides with the extrapolated doses.…”

Effectifity and Cost Analysis of Omeprazole and Pantoprazole for Stress Related Mucosal Disease Prophylaxis in ICU

“…Penelitian sebelumnya tentang profilaksis SRMD dan penggunaan PPI pada pesien dengan reflux esophagitis menyatakan bahwa jenis kelamin, usia dan lama rawat tidak berbeda signifikan antar kelompok terapi 6,7 . Jumlah faktor risiko yang dimiliki oleh pasien merupakan satusatunya karakteristik pasien yang memiliki perbedaan antar kelompok terapi pantoprazol dan omeprazol (p<0,05).…”

“…Walaupun terdapat perbedaan jumlah pasien pada kedua kelompok terapi, tetapi setelah dilakukan uji statistik dengan Chi Square didapat nilai p=0,512 (P>0,05) yang berarti bahwa tidak terdapat perbedaan efektivitas antara kelompok terapi pantoprazol dengan kelompok terapi omeprazol. Sebuah penelitian menyebutkan bahwa tidak terdapat perbedaan signifikan antara penggunaan omeprazol dan pantoprazol dalam menangani refluks esofagitis selama 4-8 minggu 5,7 .…”